The Severe Acute Respiratory Syndrome (SARS) causes significant mortality and no effective vaccine is available. Viruses closely related to SARS coronavirus (SARS-CoV) have been found in bats in several parts of the world, making re-emergence of SARS a distinct possibility. We propose to develop a safe inactivated and second-generation vaccine to prevent SARS. We showed that virus deleted in the small envelope (E) protein (rSARS-CoV-Delta E), or in this E protein plus six additional genes (6, 7a, 7b, 8a, 8b, and 9b) accessory for replication were attenuated in hamsters and mice. Among the deleted genes, E gene was the main one responsible for virus attenuation in the animal models tested. Thus, virus with either deleted or mutated E protein serves as a useful platform for the production of a chemically inactivated vaccine, and for the engineering of a live attenuated anti-SARS vaccine. We have shown that SARS-CoV E protein regulates host stress and unfolded protein responses and, consequent immune responses to the virus. We propose the identification and construction of rSARS-CoV including E protein mutants that elicit strong immune responses and are still attenuated.
The specific aims of this project are: (i) The construction of rSARS-CoV viruses with modified E protein mutants eliciting higher immune responses to the virus by maintaining E protein's role in morphogenesis. We hypothesize that preventing the interaction of E protein with host cell proteins involved in stress response signaling will lead to an enhanced immune response. E protein mutant construction will be based on the generation of an rSARS-CoV with a mutator phenotype. (ii) To test rSARSCoV-E* as vaccine candidates in mice using a mouse adapted prototype. We will analyze the immune responses to selected vaccine candidates, and the influence of non-essential group specific genes and of age. (iii) To increase the safety and titer of selected rSARS-CoV-E* vaccine candidates by modification of replicase genes, and to increase vaccine candidate titers using a virus with mutator phenotype.
This proposal describes the development of a novel attenuated vaccine that will protect against SARS as no vaccine is available. The possibility of recurrence exists, since SARS-like CoV are present in bats. Thus, it is important to develop a vaccine that will be safe and immunogenic in order to protect human populations in future outbreaks of this disease.
|Channappanavar, Rudragouda; Fett, Craig; Mack, Matthias et al. (2017) Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J Immunol 198:4046-4053|
|Fehr, Anthony R; Channappanavar, Rudragouda; Perlman, Stanley (2017) Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. Annu Rev Med 68:387-399|
|Park, Jung-Eun; Gallagher, Tom (2017) Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides. Virology 511:9-18|
|Zhao, Jingxian; Alshukairi, Abeer N; Baharoon, Salim A et al. (2017) Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol 2:|
|Chi, Hang; Zheng, Xuexing; Wang, Xiwen et al. (2017) DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine 35:2069-2075|
|Morales, Lucía; Oliveros, Juan Carlos; Fernandez-Delgado, Raúl et al. (2017) SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology. Cell Host Microbe 21:344-355|
|Li, Kun; Wohlford-Lenane, Christine L; Channappanavar, Rudragouda et al. (2017) Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A 114:E3119-E3128|
|Fehr, Anthony R; Jankevicius, Gytis; Ahel, Ivan et al. (2017) Viral Macrodomains: Unique Mediators of Viral Replication and Pathogenesis. Trends Microbiol :|
|Tai, Wanbo; Wang, Yufei; Fett, Craig A et al. (2017) Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol 91:|
|Zheng, Jian; Perlman, Stanley (2017) Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host. Curr Opin Virol 28:43-52|
Showing the most recent 10 out of 100 publications